Synthetic HCPs or Real HCPs? Matching the Test to the Stakes

Synthetic personas and synthetic audiences are everywhere in pharma market research this year, and many insights teams are right to be skeptical. A synthetic audience that isn't grounded in real physician responses cannot prove a message resonates with HCPs. A traditional study with real HCPs is too slow and expensive to run between every creative round. The practical answer is to stop treating this as a choice between the two, but a matching exercise where we choose the right the audience based on the decision at hand: the higher the cost of being wrong, the more real the audience has to be.

What is a synthetic audience in pharma market research?

A synthetic audience is a set of AI respondents built to reflect a defined HCP or patient population, so a brand team can put messages, concepts, or assets in front of it and get a read with no fieldwork. Individual AI respondents are often called synthetic respondents.

Quality of the synthetic respondents depends on what the audience is built from. One built on general web data can only tell you how a generic physician might react. One built on the brand's own research, such as past message tests, segmentation, and qualitative research, reflects how that brand's HCPs have actually responded before. For a closer look at how personas are constructed, see our guide to synthetic personas in pharma market research.

Synthetic HCPs vs real HCPs: how the options compare

Most brand teams choose between three levels of evidence. Each one answers a different kind of question.

The table also demonstrates why synthetic HCP research and primary market research with real HCPs work best together. Synthetic HCP cycles make it affordable to explore and iterate, while cycles with real HCPs make the results rigorous.

When a synthetic HCP read is enough

Use a synthetic audience when a wrong answer costs you a round of iteration, not a launch:

• Early exploration: screening a long list of message ideas or concepts to find the few worth taking to validate with real HCPs.
• Refinement between real studies: testing, rewording, and testing again for several rounds after primary market research points the way.
• Channel and segment versions: testing whether a shortened banner line or a segment-specific rewrite still resonates the way the original did. This is where most brand teams face the deployment gap in their messaging blueprint.
• Story flow Optimization : finding the message order that creates the most compelling story for each segment before the sequence is locked for the field. When you need a real HCP read
• Launch positioning strategy: the brand's positioning and the core messages that support it set the direction for everything that follows, so they need a full quant study with real HCPs.

 Leverage real HCPs when the decision is expensive to reverse:

• Launch execution: final campaign concepts, visual aids, and the messages that will carry the brand in market from day one.
• Indication launches and lifecycle management: new indications and expanded populations, where the brand's story has to evolve without losing what already works.
• Positioning shifts: a change in the brand's core positioning needs real HCP input, because a synthetic audience reflects HCP reactions to the brand's current state.

4 Questions to ask before trusting a synthetic read

Whether you build synthetic audiences in-house or evaluate a vendor's synthetic panels, these questions separate a useful read from a convincing demo:

1. What research is it built on? An audience grounded in the brand's own studies will reflect that brand's HCPs. One built on general data will reflect a generic or hypothetical physician.
2. Is there a real panel behind it? Synthetic personas are only as good as the human research that anchors them. Ask whether a synthetic read can be checked against real HCPs from the same source when the stakes call for it.
3. How closely does it match real HCPs and how was it validated? Strong validation reruns past message or asset testing studies, conducted with real HCPs and held back from the training data, with the synthetic audience. The extent of rank-order agreement and top-choice match indicates how faithfully the audience reflects real HCP decision-making. Not all synthetic audiences are equal, and fidelity tends to weaken where the underlying research is thin or data is weak. A reliable synthetic audience has documented boundaries.
4. How are the messages and assets tested? Persona conversations are useful for exploring and having open ended conversations. Decisions need methods such as MaxDiff, conjoint, and trade-off exercises, which show what HCPs choose, not only what they say.

How Marketing Asset Testing (MAT) uses both

Marketing Asset Testing (MAT) by ZoomRx is an AI-powered pharma message and marketing asset testing application that replaces long studies with turnkey, cost-effective, iterative tests. It is built on Sagan Agents. It lets a brand team test in three ways, depending on the stakes: fully synthetic HCPs, synthetic HCP read augmented with real HCPs, or a traditional full primary market research study with all real HCPs.

• Built on the brand's research: past studies load into Data Archive Intelligence, and synthetic personas and HCPs are built from them through Strategic Insights Agents.
• Real HCPs from the same source: short pulses and quant studies field to ZoomRx's 65K+ proprietary HCP panel through Agentic Market Research, with 10+ years of physician data behind every synthetic audience.
• Experts review and make the decisions: a ZoomRx research experts reviews each study design at approval checkpoints, and the brand team approves every set of messages or assets before it reaches respondents.
  
  

Frequently asked questions